ALSO NOTED: MedImmune working on avian flu vaccine; Avalon prices IPO; Genomic Health prices IPO; Lilly warns on ADHD drug; and

> MedImmune of Gaithersburg, Maryland, says it will work with federal researchers to see if a weakened version of the live flu virus H5N1 could create a vaccine that would prevent an outbreak of avian flu. Its stock surged on the news. MedImmune uses live virus in FluMist. Story [1]

> Avalon Pharmaceuticals of Germantown, Maryland, has priced its IPO of 2.75 million shares at $10.50 per share. Release [2]

> Genomic Health has priced its IPO of 5 million shares at $12 per share. Release [3]

> Eli Lilly plans to add a warning on suicidal thoughts to its ADHD drug Strattera. Story [4]

> An anti-emetic being developed by AP Pharma has hit its primary endpoint in a mid-stage trial. Release [5]

> Lipid Sciences plans to raise $7.2 million in a private placement. Release [6]

> Dainippon Pharmaceutical and Eisai have struck a development deal for an experimental drug for diabetic neuropathy. Release [7]

And Finally... British health officials are warning against widespread use of antidepressants for children and adolescents. Article [8]